Tham khảo Antalarmin

  1. ↑ Zoumakis, E; Rice, K. C; Gold, P.W; Chrousos, G. P (2006). “Potential Uses of Corticotropin-Releasing Hormone Antagonists”. Annals of the New York Academy of Sciences 1083 (1): 239–51. Bibcode:2006NYASA1083..239Z. PMID 17148743. doi:10.1196/annals.1367.021. 
  2. 1 2 3 4 Webster, E L; Lewis, D B; Torpy, D J; Zachman, E K; Rice, K C; Chrousos, G P (1996). “In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation”. Endocrinology 137 (12): 5747–50. PMID 8940412. doi:10.1210/endo.137.12.8940412. 
  3. ↑ Deak, Terrence; Nguyen, Kien T.; Ehrlich, Andrea L.; Watkins, Linda R.; Spencer, Robert L.; Maier, Steven F.; Licinio, Julio; Wong, Ma-Li; Chrousos, George P. (1999). “The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress1”. Endocrinology 140 (1): 79–86. PMID 9886810. doi:10.1210/endo.140.1.6415. 
  4. ↑ Nielsen, Darci M.; Carey, Galen J.; Gold, Lisa H. (2004). “Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice”. European Journal of Pharmacology 499 (1–2): 135–46. PMID 15363960. doi:10.1016/j.ejphar.2004.07.091. 
  5. ↑ McCarthy, J. R.; Heinrichs, S. C.; Grigoriadis, D. E. (1999). “Recent advances with the CRF1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications”. Current Pharmaceutical Design 5 (5): 289–315. PMID 10213797. 
  6. ↑ Chen, Y. L.; Mansbach, R. S.; Winter, S. M.; Brooks, E.; Collins, J.; Corman, M. L.; Dunaiskis, A. R.; Faraci, W. S.; Gallaschun, R. J. (ngày 23 tháng 5 năm 1997). “Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist”. Journal of Medicinal Chemistry 40 (11): 1749–1754. ISSN 0022-2623. PMID 9171885. doi:10.1021/jm960861b. 
  7. 1 2 Schoeffter, P.; Feuerbach, D.; Bobirnac, I.; Gazi, L.; Longato, R. (1999). “Functional, endogenously expressed corticotropin-releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells”. Fundamental & Clinical Pharmacology 13 (4): 484–489. ISSN 0767-3981. PMID 10456290. doi:10.1111/j.1472-8206.1999.tb00007.x. 
  8. 1 2 Gully, Danielle; Geslin, Michel; Serva, Laurence; Fontaine, Evelyne; Roger, Pierre; Lair, Christine; Darre, Valerie; Marcy, Claudine; Rouby, Pierre-Eric (tháng 4 năm 2002). “4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization”. The Journal of Pharmacology and Experimental Therapeutics 301 (1): 322–332. ISSN 0022-3565. PMID 11907190. doi:10.1124/jpet.301.1.322. 
  9. 1 2 3 Schulz, D W; Mansbach, R S; Sprouse, J; Braselton, J P; Collins, J; Corman, M; Dunaiskis, A; Faraci, S; Schmidt, A W (ngày 17 tháng 9 năm 1996). “CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.”. Proceedings of the National Academy of Sciences of the United States of America 93 (19): 10477–10482. Bibcode:1996PNAS...9310477S. ISSN 0027-8424. PMC 38410. PMID 8816826. doi:10.1073/pnas.93.19.10477. 
  10. 1 2 Lundkvist, Johan; Chai, Zhen; Teheranian, Roya; Hasanvan, Homa; Bartfai, Tamas; Jenck, François; Widmer, Ulrich; Moreau, Jean-Luc (ngày 8 tháng 8 năm 1996). “A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity”. European Journal of Pharmacology 309 (2): 195–200. ISSN 0014-2999. PMID 8874139. doi:10.1016/0014-2999(96)00337-8. 
  11. ↑ Gottowik, J.; Goetschy, V.; Henriot, S.; Kitas, E.; Fluhman, B.; Clerc, R.G.; Moreau, J.-L.; Monsma, F.J.; Kilpatrick, G.J. (ngày 1 tháng 10 năm 1997). “Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin”. Neuropharmacology 36 (10): 1439–1446. ISSN 0028-3908. doi:10.1016/S0028-3908(97)00098-1.